Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Export
Sort by: Relevance
  • Open Access Icon
  • Research Article
  • 10.33320/maced.pharm.bull.2023.69.02.002
Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with chronic myeloid leukemia treated with imatinib
  • Apr 1, 2024
  • Macedonian Pharmaceutical Bulletin
  • Bojan Labachevski + 9 more

Antioxidant status in patients with chronic myeloid leukemia (CML) is significantly decreased in comparison with healthy individuals. Oxidative stress (OS) may be associated with the pathophysiology of CML and can influence on development of resistance to imatinib. The aim of our study was to investigate the effect of Aronia melanocarpa extract (A-lixir 400 PROTECT®) on OS in CML patients treated with imatinib. In this study a total of 40 CML patients treated with imatinib for longer than 1 month were included: twenty patients were treated with imatinib and A-Lixir 400 PROTECT® (treatment group) and twenty patients were treated only with imatinib (control group). OS parameters (d-ROM, PAT and OSI) were measured at the initial visit, and after 21 and 42 days of treatment. Adjuvant treatment with A-Lixir 400 PROTECT® could lead to attenuation of OS. d-ROM and OSI in this group of patients were significantly higher at initial visit when compared to values after 21 and 42 days of treatment (p<0.05). Total antioxidant capacity (PAT) was significantly higher after 21 and 42 days of treatment initiation in comparison with the pretreatment values. In the control group no significant differences were obtained between investigated parameters at any time of measurement. We can conclude that adjuvant treatment with A-Lixir 400 PROTECT® after 21 and 42 days lead to significant reduction of OS in patients with CML treated with imatinib. Keywords: Oxidative stress, d-ROM, PAT, OSI, chronic myeloid leukemia, imatinib, Aronia melanocarpa

  • Open Access Icon
  • Research Article
  • 10.33320/maced.pharm.bull.2023.69.02.001
Respecting dignity: A fundamental element of the ethical being's existence
  • Apr 1, 2024
  • Macedonian Pharmaceutical Bulletin
  • Ljupcho Chakar + 7 more

Human dignity is a pivotal concept in contemporary ethical, political, and legal discourse. However, divergent and sometimes conflicting interpretations of human dignity contribute to confusion across various discussions. Given that all human beings possess inherent moral potential, each individual is endowed with universal dignity. The extent to which people develop their moral potential varies. Discussing an individual’s dignity, as in other medical specialties, cannot be separated from forensic medicine as a distinct medical discipline. In conclusion, the authors assert that establishing medical facts, or the truth ascertained through expert examination, serves justice by ensuring dignified treatment of the deceased, their family, and relatives. Keywords: dignity, ethics, forensic medicine, human remains

  • Open Access Icon
  • Journal Issue
  • 10.33320/maced.pharm.bull.2023.69.02
69
  • Apr 1, 2024
  • Macedonian Pharmaceutical Bulletin

  • Open Access Icon
  • Journal Issue
  • 10.33320/maced.pharm.bull.2023.69.01
  • Nov 1, 2023
  • Macedonian Pharmaceutical Bulletin

  • Open Access Icon
  • Journal Issue
  • 10.33320/maced.pharm.bull.2023.69.03
  • Sep 8, 2023
  • Macedonian Pharmaceutical Bulletin

  • Open Access Icon
  • Journal Volume
  • 10.33320/maced.pharm.bull.2023.69
  • Sep 4, 2023
  • Macedonian Pharmaceutical Bulletin

  • Open Access Icon
  • Research Article
  • 10.33320/maced.pharm.bull.2023.69.03.009
Novel self-nanoemulsifying drug delivery systems containing curcumin for topical drug delivery
  • Sep 1, 2023
  • Macedonian Pharmaceutical Bulletin
  • Liza Józsa + 2 more

  • Open Access Icon
  • Research Article
  • Cite Count Icon 1
  • 10.33320/maced.pharm.bull.2023.69.03.028
Azelaic acid nanosuspensions stabilized by chitosan and hydroxypropyl methylcellulose
  • Sep 1, 2023
  • Macedonian Pharmaceutical Bulletin
  • Sandra Miočić + 4 more

  • Open Access Icon
  • Research Article
  • 10.33320/maced.pharm.bull.2023.69.03.086
Lubrication effect of three novel lubricants in comparison to some commonly used lubricants
  • Sep 1, 2023
  • Macedonian Pharmaceutical Bulletin
  • Yasmin Al-Eryain + 2 more

  • Open Access Icon
  • Research Article
  • 10.33320/maced.pharm.bull.2023.69.03.075
Application of classification trees technique in optimization of parameters of production of film-coated tablets
  • Sep 1, 2023
  • Macedonian Pharmaceutical Bulletin
  • Jovana Kovačević + 6 more